Sign in
Taking peoplePhase 2/3

Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2)

Key facts

Who runs it
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
Where
Belgium, Czechia, Netherlands, and Spain10 sites in 4 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 2/3
People taking part
98 people, planned
Started
1 Jan 2024
Expected to end
30 Jun 2029
Type of study
Interventional
Record updated
2 June 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Woman ≥ 18 years
  • Beta HCG level of 14 mIU/mL or below for women of childbearing potential
  • Highly effective contraception for patients if the risk of conception exists
  • Highly effective contraception for patients if the risk of conception exists
  • Signed and written informed consent
  • Histologically-confirmed primary or recurrent squamous cell carcinoma vulvar cancer FIGO stage Ib – IVa, T1b or higher, any N, M0
  • Local tumour through which the size or localization implies requirement of treatment through primary chemoradiation or surgery consisting of extensive surgery (meaning surgery damaging pelvic organs or exenterative surgery). This can imply: T1b or larger tumour with (irresectable) groin metastases. Or this can imply: T1b or larger tumour with a close relationship to and/or involvement of the urethra or anal sphincter
  • World Health Organization performance status of 0‐2
  • Adequate haematological function defined by platelet count >100x10E9/L, absolute neutrophil count >1.5x10E9/L, and hemoglobin >6.0 mmol/L
  • Adequate hepatic function defined by a total bilirubin level ≤1.5x the upper limit of normal range and ASAT and ALAT levels ≤2.5x ULN for all subjects
  • Adequate renal function defined by an estimated creatinine clearance ≥50mL/min according to the Cockroft-Gault formula (or local institutional standard method)

Who cannot take part

  • Prior radiotherapy to the pelvis or groin area limiting full dose chemoradiation according to protocol
  • Existing neuropathy which will hinder the intake of chemotherapy
  • Any psychiatric condition that would prohibit the understanding or rendering of informed consent
  • Patients with highly suspicious or positive metastases to the pelvic lymph nodes
  • Patients eligible for radical local excision without involvement of other organs
  • Contra-indication to paclitaxel, cisplatin or carboplatin as stated in the SmPC

This trial is currently available in Belgium, Czechia, and Netherlands.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of this trial is to compare the efficacy and safety of primary chemoradiation with neoadjuvant chemotherapy (NACT) followed by surgery in patients with LAVC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
2 June 2026